Stockreport
Edwards Lifesciences (EW): Assessing Valuation After Recent Share Price Strength [Yahoo! Finance]
Last edwards lifesciences corporation earnings: 4/23 04:15 pm
Check Earnings Report
US:NYSE Investor Relations: ir.edwards.com
See our latest analysis for Edwards Lifesciences. At around $86.23 per share, Edwards Lifesciences has seen its recent share price returns strengthen, with the solid 90 day share price return hinting that investors are growing more comfortable with its growth profile despite a softer 5 year total shareholder return. If this kind of steady momentum in a specialised medical name interests you, it is worth exploring other healthcare stocks that could be shaping the next leg of your portfolio's growth. With shares climbing and analysts still seeing modest upside to their price targets, the key question now is whether Edwards Lifesciences is trading below its true potential or if the market has already priced in its next wave of growth. With Edwards Lifesciences last closing at $86.23 against a narrative fair value near $95, this framework implies the stock still trades below its long term potential. The expected approval of the early TAVR indication in the second quarter, along
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | EW | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
EW alerts
EW alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
EW alerts
High impacting Edwards Lifesciences Corporation news events
Weekly update
A roundup of the hottest topics
EW
NEWS
NEWS
- HALPER SADEH LLC ENCOURAGES EDWARDS LIFESCIENCES CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS[PR Newswire]
- FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy[Business Wire]
- 4 Large-Cap MedTech Stocks to Keep Winning Streaks Alive in 2026 [Yahoo! Finance][Yahoo! Finance]
- Relief Cardiovascular Appoints Harry Rowland as Chairman of the Board [Yahoo! Finance][Yahoo! Finance]
- Edwards Lifesciences (NYSE:EW) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $100.00 price target on the stock, up previously from $90.00.[MarketBeat]
- More
EW
SEC Filings
SEC Filings
- 12/12/25 - Form 4
- 12/12/25 - Form 4
- 12/12/25 - Form 4
- EW's page on the SEC website
- More